Ardelyx, Inc. (ARDX): EBITDA
-$37.92M
Year ended 2025-12-31
-$32.11M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$37.92M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$25.89M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$61.98M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$62.62M | n/m | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | -$151.54M | n/m | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | -$88.24M | n/a | 2023-03-02, From 2020-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$37.92M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | -$214.42M | n/m |
| MannKind Corp (MNKD) | 2025-12-31 | $51.09M | -36.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $38.59M | +12.5% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | -$2.08M | n/m |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$517.98M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $2.11M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$25.85M | n/m |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$25.16M | n/m |
Compare ARDX, ZLAB, MNKD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗